The Potential Role of BMAA in Neurodegeneration

  • Neurotox Res. 2018 Jan;33(1):222-226. doi: 10.1007/s12640-017-9752-7.
Tracie Caller  1  2  3 ,  Patricia Henegan  4 ,  Elijah Stommel  4
Affiliations
  • 1. Department of Neurology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 03756, USA. [email protected].
  • 2. Cheyenne Regional Medical Group, Cheyenne, WY, 82001, USA. [email protected].
  • 3. Institute for Ethnomedicine, PO Box 3464, Jackson, WY, 83001, USA. [email protected].
  • 4. Department of Neurology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 03756, USA.
PMID: 28612294 DOI: 10.1007/s12640-017-9752-7
Abstract

Neurodegenerative diseases are a major public health issue throughout the world with devastating effects on patients and families. Sporadic forms of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis are generally thought to develop as a consequence of genetic susceptibility and environmental influences. A number of environmental triggers have been identified in association with amyotrophic lateral sclerosis and Parkinson's disease. We discuss the role of β-methylamino-L-alanine in the development of neurodegeneration and the potential importance of this neurotoxin as a risk for neurodegeneration.

Keywords
Alzheimer’s disease; Amyotrophic lateral sclerosis; Neurodegeneration; Parkinson’s disease; β-methylamino-L-alanine.
Products